RxDoctor Payments Data

Ylonka Garcia Marotta, MD

Family Medicine · Paterson, NJNPI 1215190178

Payments from drug & device makers

$2,484in general payments, 2019–2025

Across 136 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$637
  • AstraZeneca$369
  • Amgen$196
  • Merck$188
  • Astellas Pharma US Inc$187
  • Inari Medical, Inc.$133
  • plus $774 from 15 others

What the payments were for

  • Food & beverage$2,39696%
  • Education$884%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,484 in reported general payments places this provider in the 75th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$18,497
Medicare patients
51
Services billed
192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide36$71,320
JanuviaSitagliptin Phosphate48$63,325
JardianceEmpagliflozin48$60,903
EliquisApixaban32$52,413
OzempicSemaglutide37$43,477
Janumet XrSitagliptin Phos/Metformin Hcl38$31,735
JanumetSitagliptin Phos/Metformin Hcl26$30,913
LinzessLinaclotide27$25,106
TradjentaLinagliptin18$18,753
FarxigaDapagliflozin Propanediol13$11,731
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$4,226
Humalog Kwikpen U-100Insulin Lispro22$3,704
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$3,614
Atorvastatin Calcium272$3,109
Rosuvastatin Calcium96$2,226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet Xr, Janumet$188$125,973112 claims
Boehringer IngelheimJardiance, Tradjenta$44$79,65666 claims
Lilly USA, LLCTrulicity$102$71,32036 claims
PfizerEliquis$44$52,41332 claims
Novo NordiskOzempic$637$43,47737 claims
AstraZenecaFarxiga$369$11,73113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Paterson

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →